XKEM aktuel empfohlen unter:

damen, na - da haste dir aber was vorgenommen.
da du ja noch ein paar aktien von xechem hast - mich nervt hier an dem thread, das kein listenfilter da ist ... Vielleicht lohnt sich ein neuer !   limi  

 

2006-12-08 06:30 ET - News Release


NEW BRUNSWICK, N.J. -- (Business Wire)

Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, the Chairman and CEO of Xechem International, will present at the 10th Annual New York Society of Security Analysts Biotech/Specialty Pharma Industry Conference in New York City on Tuesday, December 12th, 2006. He is scheduled to speak at 3:10 pm (EST). Dr. Pandey’s presentation will cover the significant progress in Nigeria for production and distribution of Xechem’s recently approved Sickle Cell drug NICOSAN™. In addition, Dr. Pandey will discuss Xechem’s new Sickle Cell product 5-HMF, a small-molecular compound, which has shown great promise in the preliminary studies with transgenic (Tg) mice, that will be developed as an injectable for acute episodes. Dr. Pandey’s presentation will be webcast live through a link on the Xechem website (www.xechem.com).

About NICOSAN™

NICOSAN™ is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell “crises” while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.

About 5-HMF

5-HMF is a pure natural compound developed by Professor Donald Abraham and his group at Virginia Commonwealth University (VCU). Studies carried out at VCU and Children’s Hospital of Philadelphia (CHOP) has shown 5-HMF has high affinity for sickle cell haemoglobin and thus the most promising molecule to treat Sickle Cell Disease (SCD). Preliminary animal studies show that 5-HMF is orally active with high bioavailability and has high red cell membrane permeability with very little, if any, toxicity. Xechem has license for 5-HMF from VCU for research, development, worldwide sales and marketing. Xechem received Orphan Drug Designation for 5-HMF from US-FDA on June 6th, 2006.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby.Such forward-looking statements involve known and unknown risks and uncertainties.  

hast du dir das mal durchgelesen??
Ich gestehe, ich hatte mit der aktie bisher nur das beliebte quicky spielchen gemacht.
Aber die story ist ja wirklich nicht schlecht.
limi  

Ja die Story ist super! Zieht sich aber ewig hin...  

 

 

NobleTrading, Flat Fee Online OTCBB and Pink Sheet Trading

2006-12-12 10:00 ET - News Release

Also News Release (U-GRMU) GREM USA
Also News Release (U-MENV) MICRON ENVIRO SYSTEMS NEW

NEW YORK, NY -- (MARKET WIRE) -- 12/12/06

NobleTrading.com, Inc., a leader in the online direct access trading industry, is pleased to announce its new pricing for electronic trading of all OTCBB and Pink Sheet stocks. All new customer accounts can trade unlimited number of shares for a flat fee of $9.95 per transaction. Unlike many of the other leading online brokers, NobleTrading clients can trade OTCBB and Pink Sheet securities online, using any of the four different trading platforms available, without any broker intervention. Broker assisted trades can be done over the phone for just $5 more per transaction.

NobleTrading.com, Inc. provides direct access to leading OTCBB market makers such as Knight Capital Group (NITE), Domestic Securities (DOMS), Citigroup (SBSH), Vertical Trading Group (VERT), Finance 500 (FANC), Lampost Capital (LAMP), as well as access to ARCA, the Archipelago ECN. Using ARCA, online investors can place bids and offers to the thousandth of a penny, as well as hide the true size of their order. Access to these market makers and ECN, allows for investor choice in how the order is routed as well as a higher level of speed of order execution.

This new level of service and pricing is beneficial for investors of all OTCBB and Pink Sheet stocks, but it is especially helpful to those investors that trade highly active securities such as, GREM USA, (OTCBB: GRMU), Xechem (OTCBB: XKEM), and Micron Enviro Systems (OTCBB: MENV), one of the smallest micro cap companies working in the Alberta oil sands. In addition, the NobleTrader Level 2 platform provides users with Level 2 market depth, historical and intraday charting, and time sales for all OTCBB securities.

For more information on this offer, or to schedule a real-time demonstration of their trading platform, please contact NobleTrading.com, Inc. at 877.872.3311, by email at info@nobletrading.com, or by visiting their website at http://www.nobletrading.com/otcbb.php. NobleTrading.com, Inc. is an NASD member Broker/Dealer, and is also a member of the NFA and SIPC. NobleTrading clients have the ability to trade equities, options and futures all from a single account, using a single trading platform.

Contact:
NobleTrading.com, Inc.
877.872.3311  

 

Die letzten Vorhersagen liegen doch ziemlich weit von der Realität weg... Schade eigentlich.  

wieder reif sein  

Xechem International Announces Hiring of a Managing Director for Xechem Pharmaceuticals Nigeria
Monday December 18, 12:41 pm ET

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) today announced that it has appointed Mr. Iretiolu Oniyide Managing Director of its Xechem Pharmaceuticals Nigeria Ltd. subsidiary. Mr. Oniyide, born in Nigeria and currently a resident of the United States, was selected for his high-level experience in pharmaceuticals, banking and government after an exhaustive, international search. He will relocate to Nigeria to head up this critical operation.

Dr. Ramesh Pandey, Chairman and CEO of Xechem International, stated, "We are very pleased with Mr. Oniyide's decision to take on this key position for Xechem Nigeria as we prepare for full-scale production of NICOSAN(TM), our groundbreaking new treatment for Sickle Cell Disease, at our new Abuja manufacturing facility. He brings a wealth of experience from a 30-year distinguished career in banking and pharmaceuticals, including three years as Chief Operating Officer of a pharmaceutical start-up company. He brings the necessary tools for the hard work ahead of us, with a unique vision, creativity and understanding of the plight of the 4 million Sickle Cell patients in Nigeria.

"Besides his strong background working with multinational corporations, their boards and officers on a wide range of disciplines including management, operations, finance, lending and business consulting, Mr. Oniyide is a former gubernatorial candidate in Nigeria who understands the intricate workings of industry and government necessary to bring our NICOSAN(TM) product from the small scale stage to mass production. He will be taking over from Col. Bhuwan Pandey, Vice President of Xechem International Operations, who has magnificently shepherded the NICOSAN(TM) project and Xechem Nigeria in Abuja since the inception of this project in 2002."

Mr. Oniyide holds a B.Sc. in Economics and International Business from New York University and an MBA in International Business from Adelphi University.

Mr. Oniyide said, "I am excited about the prospects of this challenging position, bringing a complex pharmaceutical product to full scale production. More importantly, it provides me a unique opportunity to give back to my community and provide a much needed product to end the suffering of many of my fellow citizens. I hope to live up to the high standards established by Col. Bhuwan Pandey."

Xechem Nigeria is presently engaged in small scale production of NICOSAN(TM), the first new product in decades to successfully treat the symptoms of Sickle Cell Disease. According to Dr. Pandey, "The expansion of our facility for the manufacture and delivery of NICOSAN(TM) to the millions of needy sufferers in Nigeria is our first and foremost directive".

Professor Soji Adelaja, John A. Hannah Distinguished Professor and Director of the Land Policy Institute at Michigan State University and Xechem International and Xechem Nigeria Board member, said, "Ireti is a seasoned leader who will bring much needed leadership to this new phase of Xechem Nigeria's evolution. The Company is doing everything in its power to organize the resources to put in place a full scale production facility and Ireti's background in the financial industry will help tremendously," Dr. Adelaja continued and said: "Raising the funds from the international community for a Nigerian-based operation designed primarily to service the Nigerian market is subject to all the challenges of the marketplace, but we are determined to make this vision a reality."

Nigeria's Minister of Health, Professor Eyitayo Lambo, said, "We are very supportive of the efforts of Xechem Nigeria to move from a small scale to a full scale production facility, which once completed, will provide hope for millions of Sickle Cell sufferers. We welcome the addition of Mr. Oniyide as Managing Director. He brings an intimate knowledge of the community and pharmaceuticals to Xechem Nigeria."

Nigeria's Minister of Science and Technology, Dr. Turner Isoun, stated, "We are all proud of Xechem Nigeria, particularly of Dr. Ramesh Pandey, who has developed the necessary state-of-the-art facilities in the Science Village, SHESTCO, Abuja, to bring NICOSAN(TM), a phytopharmaceutical product from natural plant extracts found in Nigeria, to combat Sickle Cell Disease, one of the most debilitating diseases on the continent and throughout the world."

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), diabetes, cancer, malaria, antibacterial, antifungal and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another Sickle Cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.

 

den Boden  

Xechem Update From The Recent 10th Annual NYSSA Biotech Conference
Wednesday December 20, 6:30 am ET

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that Xechem was well received and applauded for Dr. Pandey's work in developing and bringing to market the best treatment in 30 years to relieve the suffering of patients from Sickle Cell Disease (SCD) in Nigeria and throughout the world at the 10th Annual New York Society of Security Analysts Biotech Conference, December 12th/13th, 2006. Some of the highlights given by Dr. Pandey at the conference were: revenues in the first year of full production are estimated to be in the $30 million range, with a 3 to 5 year outlook of $75 - $100 million in Nigeria alone, assuming current pricing and further premised upon Xechem procuring necessary financing, receiving continued regulatory approval from Nigeria and completing construction of the Nigeria manufacturing plant; Worldwide market for Sickle Cell treatment is believed to be 16-18 million patients, with 10 million in Africa; the Nigerian government has raised the priority of Sickle Cell Disease to number two following AIDS at number one. They have also stated that the Nigerian Government will help pay for the treatment of those individuals that cannot pay for NICOSAN(TM). Dr. Pandey's presentation can be accessed through the Xechem Web Site at www.xechem.com.

Dr. Pandey introduced the new Managing Director for Xechem Pharmaceutical Nigeria, Mr. Iretiolu Oniyide, who comes to the Company with a distinguished career in the banking and pharmaceutical fields for over 30 years.

Xechem is also preparing an IND application to the FDA for US clinical trials to begin on HEMOXIN(TM) which is the name of NICOSAN(TM) for the US and Europe. Five US hospitals have agreed to take part in the clinical trials. UMDNJ, Children's Hospital of Philadelphia, SUNY-Brooklyn, Thomas Jefferson and Howard University hospitals. The opening of new Xechem offices in the UK will enable future clinical trials in Europe.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetics, antimalarials, antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) for the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent limited Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.

 

auf watch  

ich im Depot :)  

jetzt nicht mehr :)  

schon Trendwende?  

 

 

 

Eure Meinung ist gefragt , was haltet ihr davon ??

 

 

http://www.pennypickers.com/JoChef/DCFValuation-XKEM.xls

 

mal sehen wie das weiter geht  

und das mögliche daraus resultierende Potential.


http://www.amalfiresearch.com/report/XKEM.pdf


gianni  

in den nächsten Tagen auch mal was tun bezüglich steigende Kurse.
Wenn es dann auch noch mit dem Volumen stimmt....  

der Anfang wäre gemacht. Mal schauen was am Montag geht.